Neurocrine Biosciences SG&A Expenses 2010-2024 | NBIX

Neurocrine Biosciences sg&a expenses for the twelve months ending December 31, 2024 were $1.007B, a 13.47% increase year-over-year.

  • Neurocrine Biosciences annual sg&a expenses for 2024 were $1.007B, a 13.47% increase from 2023.
  • Neurocrine Biosciences annual sg&a expenses for 2023 were $0.888B, a 17.92% increase from 2022.
  • Neurocrine Biosciences annual sg&a expenses for 2022 were $0.753B, a 29.04% increase from 2021.

Neurocrine Biosciences SG&A Expenses 2010-2024 | NBIX

  • Neurocrine Biosciences annual sg&a expenses for 2024 were $1.007B, a 13.47% increase from 2023.
  • Neurocrine Biosciences annual sg&a expenses for 2023 were $0.888B, a 17.92% increase from 2022.
  • Neurocrine Biosciences annual sg&a expenses for 2022 were $0.753B, a 29.04% increase from 2021.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$79.9B
Zoetis (ZTS)$70.1B
Daiichi Sankyo, - (DSNKY)$43.9B
Takeda Pharmaceutical (TAK)$43.7B
Sandoz Group AG (SDZNY)$20.6B
Merck (MKKGY)$18.3B
Astellas Pharma (ALPMY)$17.4B
United Therapeutics (UTHR)$17B
Summit Therapeutics (SMMT)$15.9B
Shionogi (SGIOY)$12.3B
Corcept Therapeutics (CORT)$7.7B
Madrigal Pharmaceuticals (MDGL)$7.5B
Orion OYJ (ORINY)$7.4B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Stevanato Group S.p.A (STVN)$6.2B
Grifols, S.A (GRFS)$5.1B
Ionis Pharmaceuticals (IONS)$5B
Ono Pharmaceutical (OPHLF)$4.7B
Recursion Pharmaceuticals (RXRX)$4.2B
Crinetics Pharmaceuticals (CRNX)$3.4B
Catalyst Pharmaceuticals (CPRX)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.4B
Hypermarcas (HYPMY)$2.2B
Centessa Pharmaceuticals (CNTA)$2.1B
Soleno Therapeutics (SLNO)$2B
BioCryst Pharmaceuticals (BCRX)$1.9B
NewAmsterdam Pharma (NAMS)$1.8B
Evotec AG (EVO)$1.6B
Ardelyx (ARDX)$1.5B
Indivior (INDV)$1.5B